Medical Doctor Program year 2023 Reported 2020–2023 Source: CMS Open Payments, 2026 publication

Thomas Hendrick

Inverness, FL Medical Doctor

NPI 1548238389 CMS profile 1302981

403 W Highland Blvd, Inverness, FL 34452

Open in the dashboard

General payments

$250

12 records reported · program years 2020–2023

Research payments

$0

Paid to them · None reported · program years 2020–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Thomas Hendrick of Inverness, FL is reported in the CMS Open Payments database as having received $250 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $46 2
2022 General $13 1
2021 General $118 5
2020 General $73 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Hendrick
  • Florida median
  • Middle half of Florida
  • National median

In program year 2025, general payments to Thomas Hendrick were reported at $0. Among 84,641 Florida profiles paid that year, the median was $195 and the middle half received between $59 and $690.

Show as a table
Year Thomas Hendrick Florida median Middle half National median
2019 $0 $197 $63–$719 $163
2020 $73 $126 $38–$436 $114
2021 $118 $151 $45–$537 $132
2022 $13 $175 $53–$607 $149
2023 $46 $183 $57–$637 $160
2024 $0 $185 $56–$647 $164
2025 $0 $195 $59–$690 $169

Breakdown

Who paid General payments · program years 2020–2023
  1. Organogenesis Inc. $96 4 payments
  2. Medline Industries, Inc. $40 2 payments
  3. Aroa Biosurgery Incorporated $32 1 payment
  4. Smith+Nephew, Inc. $28 2 payments
  5. KCI USA, Inc $25 1 payment
  6. Apria Healthcare LLC $16 1 payment
  7. Milliken Healthcare Products, LLC $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2023
  1. Food and Beverage $250 12 payments
Products named General payments · program years 2020–2023
  1. Puraply Antimicrobial $56 2 payments
  2. Puraply $39 2 payments
  3. KerraCel Ag $25 1 payment
  4. Coban $25 1 payment
  5. IoPlex Iodophor Foam Dressings Dermatology/Wound Care $20 1 payment
  6. IoPlex Iodophor Foam Dressings Lab Supplies $19 1 payment
  7. Invacare $16 1 payment
  8. Philips $16 1 payment
  9. Medela $16 1 payment
  10. Resmed $16 1 payment
  11. Other $99 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$1,165

Medicare's payments for the services billed

Medicare patients

14

Average age 76

Services billed

52

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record